CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer

(2017) Somala Mohammed et al.   MOLECULAR THERAPY

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9

(2016) Richard Beatson et al.   NATURE IMMUNOLOGY

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

(2016) Fengtao You et al.   Science China-Life Sciences

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

(2016) Dawei Shou et al.   Oncotarget

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growth

(2015) Katherine T. Venmar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting IL4/IL4R for the treatment of epithelial cancer metastasis

(2015) Katherine Venmar Bankaitis et al.   CLINICAL & EXPERIMENTAL METASTASIS

MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad

(2015) Lacey Haddon et al.   CLINICAL & EXPERIMENTAL METASTASIS

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

IL4 Receptor ILR4  Regulates Metastatic Colonization by Mammary Tumors through Multiple Signaling Pathways

(2014) K. T. Venmar et al.   CANCER RESEARCH

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor

(2014) Ann M Leen et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

MUC1: a multifaceted oncoprotein with a key role in cancer progression

(2014) Sritama Nath et al.   TRENDS IN MOLECULAR MEDICINE

Lessons from immunology: IL4R directly promotes mammary tumor metastasis

(2014) Katherine T Venmar et al.   OncoImmunology

Optimizing the production of suspension cells using the G-Rex “M” series

(2014) Pradip Bajgain et al.   Molecular Therapy-Methods & Clinical Development

Myeloid-derived suppressor cells in breast cancer

(2013) Joseph Markowitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells

(2013) Usanarat Anurathapan et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

MUC1 and metastatic cancer

(2013) Teresa M. Horm et al.   Cell Adhesion & Migration

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Regulation of innate CD8+ T-cell activation mediated by cytokines

(2012) B. E. Freeman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulatory T cells increase in breast cancer and in stage IV breast cancer

(2011) Zhi-kuan Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor

(2011) Yozo Nakazawa et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Regulatory T cells and breast cancer: implications for immunopathogenesis

(2010) Maria Angelica Ehara Watanabe et al.   CANCER AND METASTASIS REVIEWS

Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: Do they protect breast cancer cells from the immune response?

(2010) Mahboobeh Razmkhah et al.   CELLULAR IMMUNOLOGY

Inflammatory cytokines as a third signal for T cell activation

(2010) Julie M Curtsinger et al.   CURRENT OPINION IN IMMUNOLOGY

Over-expression of ST3Gal-I promotes mammary tumorigenesis

(2010) Gianfranco Picco et al.   GLYCOBIOLOGY

CAR Mechanics: Driving T Cells into the MUC of Cancer

(2009) J. Maher et al.   CANCER RESEARCH

Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7

(2009) Juan F Vera et al.   MOLECULAR THERAPY

Cytokine Comparisons Between Women With Breast Cancer and Women With a Negative Breast Biopsy

(2009) Debra E. Lyon et al.   NURSING RESEARCH

Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer

(2009) N Khodarev et al.   ONCOGENE

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

(2008) M Todaro et al.   CELL DEATH AND DIFFERENTIATION